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Dang Gui Bu Xue Tang (DBT), a Chinese medicinal decoction contains Radix Angelicae sinensis (Danggui) and Radix Astragali
(Huangqi) at a ratio of 1:5, is used commonly for treating women’s ailments. This study was conducted to explore the
eﬀects of this preparation on insulin resistance in rats fed with 6-week diet containing 60% fructose. Similar to the action of
rosiglitazone (4mgkg−1 per day by an oral administration), repeated oral administration of DBT (2.5gkg−1 per day) for 14
days was found to signiﬁcantly alleviate the hyperglycemia but made no inﬂuence on plasma lipid proﬁles nor weight gain in
fructose chow-fed rats. Also, the higher degree of insulinresistance as measured by homeostasismodel assessmentof basalinsulin
resistance in fructose chow-fed rats was signiﬁcantly decreased by repeated DBT treatment. DBT displays the characteristic of
rosiglitazoneby increasing the whole-body insulin sensitivityin fructose chow-fed rats after 2-week treatment, as evidenced by the
marked elevation of composite whole-body insulin sensitivity index during the oral glucose tolerance test. DBT improves insulin
sensitivity through increased post-receptor insulin signalingmediated by enhancements in insulin receptor substrate-1-associated
phosphatidylinositol3-kinase step and glucose transporter subtype 4 translocationin soleus muscles of animalsexhibiting insulin
resistance. DBT is therefore proposed as potentially useful adjuvant therapy forpatients with insulin resistance and/or the patients
who wish to increase insulin sensitivity.
1.Introduction
Insulin resistance, a metabolic disorder raised seriously
around the world, characterized by a diminished ability of
insulin-sensitive tissues and a marked decrease of glucose
metabolism in response to insulin resulting from complex
interactions between genetic and environmental factors, is
associated with some common diseases including type-2
diabetes, hypertension, obesity, and coronary heart disease
[1]. The use of pharmacological intervention in addition
to lifestyle modiﬁcations with weight loss and moderate
exercise is accepted as a positive factor in health, and these
are viewed as particularly useful in the management of
obesity and cardiovascular diseases as well as prevention of
insulin resistance and type-2 diabetes mellitus [2]. Thiazo-
lidinediones (TZD), agonists of the peroxisome proliferator-
activated receptor (PPAR)γ, enhance insulin sensitivity and
improve metabolic control in patients with type-2 diabetes
[3]. Despite the proven eﬃcacy, a number of deleterious side
eﬀects of TZDs, including rosiglitazone and pioglitazone,
have been noted such as weight gain and the documented
aggravation of advanced heart failure through ﬂuidretention
[4]. Accordingly, eﬀorts have been mounted to generate
modulators that retain the beneﬁcial clinical eﬀects while
avoiding these side eﬀects. It seems, therefore, that develop-
ment of new agents may be helpful in the therapy of diabetic
patients with insulin resistance.
Dang Gui Bu Xue Tang (DBT), also known as Tangkuei
and Astragalus Decoction, is widely employed in tradi-
tional Chinese medicine (TCM) because of the marked
hematopoietic properties of this preparation [5]. In Man-
darin, the herb Angelica sinensis is named as Dang Gui,
Bu Xue refers to hematopoietic eﬀects, and Tang is the
term for solution. DBT was formulated originally during
the Jin Dynasty and contained two main ingredients, Radix
Angelicae sinensis (Danggui) and Radix Astragali (Huangqi)2 Evidence-Based Complementary and Alternative Medicine
in a ratio of 1:5 [6, 7]. At this ingredient ratio, DBT
has been found to reduce menopausal symptoms [8]. This
formulatreats consumptivefatigueandinternalinjurywhich
causes deﬁcient Qi and blood, and “ﬂoating yang” appears
externally. Recent ﬁndings indicate that DBT has the ability
topromotehematopoieticfunction, stimulatecardiovascular
circulation, prevent osteoporosis and antagonize the activity
of tumors [6, 9]. Actually, DBT has an ability to lower
higher plasma glucose in streptozotocin-induced diabetic
rats (STZ-diabetic rats), the type-1 diabetes-like animal
model [7]. Additionally, DBT has been found to retard the
progression of diabetic nephropathy through suppression
of transforming growth factor-β1 gene expression in STZ-
diabetic rats [7]. It seems that this traditional Chinese herbal
preparation is valued in the glucose homeostasis, and may
therefore utilize as adjuvant therapy for control of diabetes
anditscomplications.However,littleinformationisavailable
regarding the eﬀect of DBT on insulin resistance.
The consumption of fructose worldwide has largely
increased due to an increased consumption of soft drinks
and other beverages that are high in fructose, and due to the
consumption of breakfast cereals, baked goods and prepared
desserts sweetened with high-fructose corn syrup. Studies
in rats have demonstrated that a high intake of fructose
produced a decline of insulin sensitivity in the liver and
peripheral tissues [10]. Hence, fructose has been implicated
as a useful tool in inducing insulin resistance in animals.
Thus, for this study, we employed rats with insulin resistance
induced by the diet containing 60% fructose to investigate
the eﬀect of DBT on insulin resistance.
2.Methods
2.1. Materials. The water decocted concentrated powders
for DBT (Cat. no KPC3570) was produced by Kaiser
Pharmaceutical Co., Ltd (Tainan, Taiwan) under interna-
tionally certiﬁed good manufacturing practices guidelines.
The product was registered (Code no 015648) by Committee
on Chinese Medicine and Pharmacy, Department of Health,
Executive Yuan, (Taiwan). The ratio of Radix A. sinensis
(Danggui) and Radix Astragali (Huangqi) used in DBT is
1:5 [6, 7]. The experienced botanists and chemists of the
supplier use macroscopic and microscopic examinations as
well as thin-layer chromatography and high-performance
liquid chromatography identiﬁcation to authenticate the
plants, plant parts used and process raw herbs. The reference
specimens were deposited at the herbarium of the supplier.
Standard rat chow containing 60% vegetable starch, 5%
fat and 18% protein (Cat. no #2018) and fructose-rich rat
chow containing 60% fructose, 5% fat and 18% protein
(Cat. no #TD 89247) were obtained from Harlan Teklad
(Madison, WI). Protein A-Sepharose beads were purchased
from Sigma-Aldrich, Inc. (St Louis, MO). Rosiglitazone
maleate (Avandia) was from GlaxoSmithKline (Research
Triangle Park, NC). The diagnostic kits for determina-
tions for plasma levels of glucose (Cat. no COD12503),
cholesterol (Cat. no COD11539) and triglyceride (Cat. no
COD11529) were purchased from BioSystem (Barcelona,
Spain). Rat insulin enzyme-linked immunosorbent assay
(ELISA) kit was obtained from Linco Research, Inc. (St
Charles, MO; Cat. no #EZRMI-13K). The kit for protein
assay was purchased from Bio-Rad Laboratories (CA, USA).
Anti-insulin receptor (IR) β-subunit antibodies (Cat. no
#MS-634 for immunoprecipitation; Cat. no #MS-636 for
western blotting), anti-insulin receptor substrate (IRS)-
1 antibody (Cat. no #MS-630) and anti-phosphotyrosine
antibody (Cat. no #MS-445) were obtained from NeoMark-
ers (Fremont, CA, USA). Anti-phosphatidylinositol (PI) 3-
kinase p85 antibody (Cat. no #4292), anti-Akt antibody
(Cat. no #9272), anti-phospho-Ser473Akt antibody (Cat. no
#9271), anti-phospho-Thr
308Akt antibody (Cat. no #9275),
anti-phospho-(Ser/Thr) Akt substrate antibody (Cat. no
#9611) and anti-glucose transporter subtype 4 (GLUT 4)
antibody(Cat.no#2299)werepurchased fromCellSignaling
Technology (Beverly, MA). Anti-AS160 (Rab GAP) antibody
was obtained from Upstate (Charlottesville, VA; Cat. no #07-
741). ECL Western Blotting Systems were obtained from
Amersham Corp. (Braunschweig, Germany). Bovine insulin
was obtained from NovoNordisk (Bagsvaerd, Denmark). All
other reagents were obtained from standard sources.
2.2. Animal Models. Male Wistar rats aged 8 weeks were
obtained from the National Laboratory Animal Center
(Taipei, Taiwan). They were maintained in a temperature-
controlled room (25 ±1◦C) and kept on a 12:12 light-dark
cycle (light on at 06:00h) in our animal center. Food and
water were available ad libitum. The rats were divided into
two experimental groups. One group of rats was randomly
assigned to receive the fructose chow for 6 additional weeks
to induce insulin resistance [11]. The remaining group
receiving standard chows during the 6-week period was
designated as the control group. All animal procedures were
p e r f o r m e da c c o r d i n gt ot h eG u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals of the National Institutes of Health, as
well as the guidelines of the Animal Welfare Act.
The homeostasis model assessment of basal insulin
resistance (HOMA-IR) was used to calculate an index from
the product of the fasting concentrations of plasma glucose
(mM) and plasma insulin (μUmL
−1) divided by 22.5 [12].
Lower HOMA-IR values indicated greater insulin sensitivity,
whereas higher HOMA-IR values indicated lower insulin
sensitivity (insulin resistance).
2.3. Treatment Protocols. The rats fed with 6-week fructose
chow were used as insulin-resistant animals. Powders ofDBT
were dissolved in distilled water for oral administration at
the desired doses (0.5, 1.5, 2.5gkg
−1 per day) in a volume
of 10mLkg−1 once a day into insulin-resistant rats. The
eﬀect of DBT was determined for 14 consecutive days in
subsequent experiments. Another group of fructose chow-
fed rats was treated similarly but with the same volume of
vehicle (distilled water) as was used to dissolve DBT during
the 2-week treatment period. Additionally, rosiglitazone was
given by oral gavage (4mgkg
−1 per day) once a day for
14 days to the separate groups of fructose chow-fed rats.
This dose was selected since it was comparable to the dose
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rats were maintained on a fructose chow diet during the 2-
week treatment period. Water was made available ad libitum
throughout the experiment.
2.4. Oral Glucose Tolerance Test. Two weeks after DBT
or rosiglitazone treatment, an oral glucose tolerance test
(OGTT) was performed using an oral of glucose (1gkg−1)
for 2h in fructose chow-fed rats. Animals were food-
restricted and were given only water to drink throughout
the night prior to the OGTT procedure. Plasma glucose
and insulin concentrations were measured before (taken as
0min) and 30, 60, 90 and 120min after the glucose load.
Insulin sensitivity was calculated using the composite
whole body insulin sensitivity index (ISIcomp) during the
OGTT [14]. ISIcomp was estimated with the formula as
following: ISIcomp = 10000/square root of ((mean plasma
insulin × mean plasma glucose during OGTT) × (fasting
plasma glucose × fasting plasma insulin)).
2.5. Blood Sampling and Analysis. Blood sample of rats
were collected from the lateral tail vein of animals anes-
thetized with sodium pentobarbital (30mgkg−1) adminis-
tered intraperitoneally (i.p.). Samples were centrifuged at
2000g for 10min at 4◦C, plasma was removed and aliquot
for the respective analytical determinations. Plasma glucose
concentration was measured by glucose oxidase method
(Hitachi 717 autoanalyzer; Hitachi Ltd, Tokyo, Japan). Levels
of cholesterol and triglycerides in total plasma were analyzed
enzymatically (Hitachi 717 autoanalyzer). The ELISA was
employed to quantify the plasma insulin level using a
commercially available kit. The test compounds used in this
study did not aﬀect the binding of peptide with antibodies.
All samples were analyzed in triplicate.
2.6. In Vivo Insulin Receptor Activation. To assess DBT on
insulin receptor activation in vivo,r a t si nt h ef e ds t a t ew e r e
anesthetized with sodium pentobarbital at the end of the 2-
week treatment period. Then, a bolus of insulin (10Ukg−1)
was injected into portal vein of rats, as described previously
[15]. Approximately 120s after insulin injection, rats were
sacriﬁced and the soleus muscle was immediately extirpated,
washed with cold phosphate buﬀer and cut into 200–300mg
portions, which were then stored separately at −70◦Cf o r
subsequentimmunoprecipitation and immunoblot analyses.
2.7. Muscle Processing. Cytosol and membrane fractions
were prepared according to the previous method [16].
Brieﬂy, muscles used for measuring insulin signaling were
weighed while still frozen and homogenized (Polytron,
Brinkmann Instruments, Inc., Westbury, NY) in 0.4mL
homogenizing buﬀer containing 250mM sucrose, 20mM
Tris (pH 7.5), 2mM EDTA, 0.5mM EGTA, 20μgmL
−1 leu-
peptin, 10μgmL
−1 aprotinin, 174.2μgmL
−1 phenylmethyl-
sulfonyl ﬂuoride and 20mM dithiothreitol. The homogenate
was centrifuged at 100000g for 1h at 4◦C. The supernatant
(cytosolic extract) was transferred to a tube kept on ice,
whereasthepelletwasresuspendedin0.45mLhomogenizing
buﬀer containing 5% Triton X-100. The resuspended pellet
fraction was then centrifuged at 14000g for 5min at 4◦C,
and the pellet was discarded. The supernatant from this spin
constitutes the membrane extract. Protein concentrations
were determined by the BioRad protein dye binding assay.
The supernatant was stored at −80◦C until used in immuno-
precipitation and western immunoblotting.
2.8. Immunoprecipitation. Muscle lysate (500μg) was sub-
jected to immunoprecipitations with anti-IR β-subunit
antibodies, anti-IRS-1 antibody, or anti-AS160 (Rab GAP)
antibody at 4◦C overnight, followed by shaking with protein
A-Sepharose beads for 1h. The bead-Protein A-antibody-
antigen complexes were precipitated by brief centrifugation.
The pellets were washed three times in ice-cold buﬀer (0.5%
Triton X-100, 100mM Tris, pH 7.4, 10mM EDTA and 2mM
sodium vanadate), resuspended in Laemmli sample buﬀer
and boiled for 5min. The sepharose beads were precipitated
by brief centrifugation and the supernatant prepared for
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE, 10% acrylamide gel) using a Bio-Rad Mini-
Protein II system (55 and 130V during the stacking and
separation phases, resp.). Protein was transferred to a
polyvinylidene diﬂuoride (PVDF) membrane using the Bio-
Rad Trans-Blot system (2h at 20V in 25mM Tris, 192mM
glyceineand20%MeOH).Followingtransfer, themembrane
was probed with anti-IR β-subunit antibody, anti-IRS-1
antibody, anti-phosphotyrosine antibody, anti-p85 subunit
of PI 3-kinase antibody or anti-AS160 antibody according to
the manufacturers’ instructions.
2.9. Immunoblotting. Equal amounts (50μg) of protein were
prepared from muscle homogenates, subjected to SDS-
PAGE, transferred to PVDF membrane as described above,
and blotted with anti-PI 3 kinase p85 antibody, anti-
Akt antibody and anti-GLUT 4 antibody, according to the
manufacturer’s instructions. Protein phosphorylation of Akt
was measured using the anti-phospho-Ser473Akt antibody
and anti-phospho-Thr
308Akt antibody. Phosphorylation of
Akt substrate of 160kDa (PAS-AS160) was detected using
the anti-phospho-(Ser/Thr) Akt substrate antibody. PAS
recognizes Akt phosphorylation motif peptide sequences
(RXRXXpT/S). After three 5min washes in TBST (20mM
Tris-HCl (pH 7.5), 150mM NaCl and 0.05% Tween 20),
membranes were incubatedwith the appropriateperoxidase-
conjugated secondary antibodies. The membranes were then
washed three times in TBST and visualized on X-ray ﬁlm
using the enhanced chemiluminescence detection system.
Densitiesoftheobtainedimmunoblotswerequantiﬁedusing
a laser densitometer. The mean value for samples from
vehicle-treated standard chow-fed rats on each immunoblot,
expressed in densitometry units, was adjusted to a value
of 1.0. All experimental sample values were then expressed
relative to this adjusted mean value.
2.10. Statistical Analysis. Data are expressed as the mean ±
SD for each group of animals at the number (n) indicated in
tables. Statistical diﬀerences among groups were determined
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range post-hoc comparisons were used to determine the
sourceofsigniﬁcantdiﬀerenceswhereappropriate.AP-value
<.05 was considered statistically signiﬁcant.
3.Results
3.1. General Characteristics of Rats. Animals maintained on
the 6-week high-fructose diet exhibited signiﬁcant hyper-
glycemia and hyperinsulinemia compared with the standard
chow-fed group for the same feeding period (Table 1).
Plasma glucose levels in fructose chow-fed rats were sig-
niﬁcantly decreased to near those observed in the standard
chow-fed group after 2 weeks of rosiglitazone (4mgkg−1
per day) treatment (Table 1). Following the administration
of DBT at daily oral dosage of 2.5gkg−1 for 14 consecutive
days, plasma glucose levels in fructose chow-fed rats fell to a
value signiﬁcantly lower than that from their vehicle-treated
counterparts (P<. 0 5 ) ,s h o w i n gap l a s m ag l u c o s e - l o w e r i n g
activity of 13.4 ± 3.1% (Table 1). DBT even at the higher
daily oral dosage inﬂuences neither the plasma insulin levels
norbody weight offructose chow-fedrats. However,fructose
chow-fed rats receiving rosiglitazone (4mgkg−1 per day)
treatment exhibited lower plasma insulin level and gained
more body weight comparing with DBT-treated groups at
the end of the 2-week treatment period (Table 1).
Plasma triglyceride level was signiﬁcantly reduced in
fructose chow-fed rats after 14 days of rosiglitazone
(4mgkg−1 per day; Table 1). Although the plasma triglyc-
eride level in fructose chow-fed rats tended to be reduced by
14 days of DBT treatment, there was no signiﬁcant diﬀerence
between any treatments in fructose chow-fed rats group
(Table 1). At the termination of 2-week treatment, the total
plasma cholesterol in fructose chow-fed rats was reduced
without signiﬁcant diﬀerences between any treatment and
those in standard chow-fed group.
The HOMA-IR score in rats feed with 6-week high-
fructose diet was higher by 3.5-fold times that of the
standard chow-fed group, which markedly fell to 47%
of their vehicle-treated counterparts following 14 days of
rosiglitazone (4mgkg−1 per day) treatment (Table 1). The
HOMA-IR score in fructose chow-fed rats receiving 2-week
DBT (2.5gkg−1 per day) treatment showed a decrease to
80%ofthescoreobservedin thevehicle-treatedcounterparts
(Table 1).
3.2. Insulin Sensitivity. Plasma glucose levels were signiﬁ-
cantly elevated during the OGTT in fructose chow-fed rats
compared to the standard chow-fed group at all time points
tested (Figure 1). In the vehicle-treated fructose chow-fed
rats, plasma glucose concentrations increased from fasting
levels of 134.5 ± 6.4mgdL
−1 to nearly 239.8 ± 7.1mgdL
−1
by 30min and were still greatly increased over baseline levels
2h after the oral glucose challenge. The fructose chow-fed
ratstreatedwithDBTfor2weeks(2.5gkg−1 perday)showed
a signiﬁcant elevation in plasma glucose concentrations at
30min but returned to basal levels within 2h after the oral
glucose administration; similar results were obtained with
rosiglitazone (4mg kg−1 per day)-treated fructose chow-fed
group (Figure 1).
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Figure 1: Plasma glucose and insulin responses during an oral
glucose (1gkg−1) tolerance test (OGTT) in fructose chow-fed rats
repeatedly receiving oral administration of DBT at 0.5gkg−1 (ﬁlled
inverted triangle), 1.5gkg−1 (open triangle) or 2.5gkg−1 (ﬁlled
square), once a day for 14 days. Rosiglitazone was given by oral
gavage (4mgkg−1 per day) for 14 days to the separate groups of
the fructose chow-fed rats (open square). The vehicle (distilled
water) used to dissolvethe tested medications was givenat the same
volume. Values (mean ± SD) were obtained from each group of
eight animals. aP <. 05 and bP <. 01 compared with the values
of vehicle-treated fructose chow-fed rats (unﬁlled circle) at the
indicated times, respectively.
Fasting plasma insulin concentrations were signiﬁcantly
greaterin fructosechow-fed ratscomparedwith thestandard
chow-fed group and remained higher at all time points
throughout the OGTT study period (Figure 1). The plasma
insulin concentrations of fructose chow-fed rats in both
DBT- and rosiglitazone-treated groups increased 30min
after the oral glucose challenge, but returned to their
respective fasting levels by 2h after OGTT; the eﬀect of DBT
was more remarkable at the daily oral dosage at 2.5gkg−1
(Figure 1).Evidence-Based Complementary and Alternative Medicine 5
Table 1: General characteristics of fructose chow-fed rats after 2 weeks of treatment.
Characteristics
Standard chow-fed Fructose chow-fed
Vehicle Vehicle DBT (gkg−1 per day) Rosiglitazone
0.5 1.5 2.5
Body weight (g/rat) 248.7 ± 9.8 266.8 ± 8.7 263.4 ± 8.4 258.5 ± 9.6 260.9 ± 9.4 302.3 ± 10.1a,c
Plasma glucose (mgdL
−1) 92.3 ± 6.1d 134.5 ± 7.2b 128.4 ± 6.4b 120.7 ± 5.8b 116.4 ± 5.1a,c 106.3 ± 5.6a,c
Plasma insulin (μUmL
−1) 21.8 ± 5.3d 50.3 ± 4.7b 49.5 ± 5.4b 48.8 ± 5.6b 48.1 ± 4.9b 30.4 ± 5.8d
Plasma triglyceride (mgdL
−1) 97.4 ± 9.4d 325.2 ± 12.1b 319.7 ± 10.7b 312.3 ± 11.8b 308.6 ± 12.4b 174.2 ± 10.5b,d
Plasma cholesterol (mgdL
−1) 85.4 ± 6.3 90.6 ± 5.9 86.5 ± 5.1 84.2 ± 6.7 83.4 ± 5.3 78.3 ± 4.7
HOMA-IR score 4.9 ± 0.7d 16.7 ± 1.3b 15.6 ± 0.9b 14.5 ± 1.0b 13.8 ± 1.1b 7.9 ± 0.8b,c
ISIcomp 3.63 ± 0.18d 0.92 ± 0.14b 1.12 ± 0.19b 1.32 ± 0.15b,c 1.53 ± 0.17b,c 2.21 ± 0.15a,c
DBT was dissolved in distilled water for oral administration at the desired doses in a volume of 10mLkg−1 once a day into rats receiving 6 weeks of fructose
chow feeding. Rosiglitazone was also given by oral gavage (4mgkg−1 per day) to the separate groups of the fructose chow-fed rats. The vehicle (distilled
water) used to dissolve the tested medications was given at the same volume. ISIcomp was calculated after a 2h OGTT. Values (mean ± SD) were obtained
from seven rats. aP <. 05 and bP <. 01 compared with the values of vehicle-treated standard chow-fed rats in each group, respectively. cP <. 05 and dP <. 01
compared with the values of vehicle-treated fructose chow-fed rats in each group, respectively.
The ISIcomp was also signiﬁcantly lower in the fructose
chow-fed group as compared to that in standard chow-
fed group. Although not as eﬀective as that produced by
rosiglitazone (4mgkg−1 per day),2 weeks ofDBT(2.5gkg−1
per day) treatment increased ISIcomp of fructose chow-
fed rats to 1.7-fold of the value in their vehicle-treated
counterparts (Table 1).
3.3. The Protein Levels and the Degree of Insulin-Stimulated
Phosphorylation of IR. Following 2-week treatment, there
was diﬀerence in the expression of IR protein in soleus
muscle of rats between any groups; treatment with either
rosiglitazone (4mgkg−1 perda y)orDBT(2.5gkg −1 perday)
did not modify these values (Figure 2, Table 2).
The degree of insulin-stimulated increment in tyrosine
phosphorylation of IR in soleus muscle was clearly lowered
in fructose chow-fed rats as relative to those from standard
chow-fed group (Figure 3). Under insulin stimulation, 2-
week rosiglitazone (4mgkg−1 per day) treatment elevated
the extent oftyrosine phosphorylation of IRin soleusmuscle
of fructose chow-fed rats to 1.9-fold of that from their
vehicle-treated counterparts (Figure 3). Also, the degree of
tyrosine phosphorylation of IR in soleus muscle of fructose
chow-fedratswasamelioratedby2-weekDBT(2.5gkg−1 per
day) treatment (Figure 3).
3.4. The Protein Levels and the Degree of Insulin-Stimulated
Phosphorylation of IRS-1. The expression of IRS-1 protein
in soleus muscles of fructose chow-fed rats was close to
50% of that in standard chow-fed group (Figure 2, Table 2).
At the end of the 2-week rosiglitazone (4mgkg−1 per day)
treatment, protein expression of IRS-1 in soleus muscles of
fructose chow-fed rats resembled that of the standard chow-
fed group (Figure 2, Table 2). Two-week DBT (2.5gkg−1 per
day) treatment also raised IRS-1 protein expression in soleus
muscles of fructose chow-fed rats, but did not achieve the
l e v e li ns t a n d a r dc h o w - f e dr a t( Figure 2, Table 2).
The insulin-stimulated IRS-1 tyrosine phosphorylation
in soleus muscles of fructose chow-fed rats following rosigli-
tazone treatment was returned to levels comparable to those
GLUT 4
AS160
Akt
PI3 K(p85α)
IRS-1
IR
Standard chow-fed Fructose chow-fed
DBT
Rosiglitazone
−− + −
−− − +
Figure 2: A Representative immunoblots of protein expression of
insulin receptor-related signaling mediators in the soleus muscles
of fructose chow-fed rats following repeated oral administration of
DBT (2.5gkg−1 per day) or rosiglitazone (4mgkg−1 per day) for
14 days. Rats that did not receive any treatment were given the
same volume of vehicle (distilled water) used to dissolve the test
medications. Findings were reproduced on four separate occasions.
Quantiﬁcation of the data is shown in Table 2.
of standard chow-fed animals (Figure 3, Table 2). Two weeks
treatment of fructose chow-fed rats with DBT (2.5gkg−1
per day) recovered the insulin-stimulated IRS-1 tyrosine
phosphorylation in soleus muscles to levels close those of
standard chow-fed animals (Figure 3, Table 2).
3.5. The Protein Levels and Activity of PI 3-Kinase. The basal
level of p85 regulatory subunit of PI 3-kinase in soleus
muscle of fructose chow-fed rats was depressed to nearly6 Evidence-Based Complementary and Alternative Medicine
Table 2: Quantiﬁcation of the speciﬁc insulin signaling proteins in soleus muscles of fructose chow-fed rats after 14-day treatment with
DBT or rosiglitazone.
Relative units Standard chow-fed Fructose chow-fed
Vehicle Vehicle DBT (2.5gkg−1 per day) Rosiglitazone (4mgkg−1 per day)
IR 1.00 ± 0.06 1.01 ± 0.06 0.98 ± 0.09 1.01 ± 0.07
IRS-1 1.01 ± 0.05d 0.48 ± 0.07b 0.78 ± 0.08a,c 0.92 ± 0.06d
PI 3 K (p85) 1.03 ± 0.06d 0.49 ± 0.05b 0.81 ± 0.06a,d 0.94 ± 0.05d
Akt 1.02 ± 0.04d 0.43 ± 0.06b 0.76 ± 0.05a,c 0.93 ± 0.08d
AS160 1.01 ± 0.05d 0.41 ± 0.07b 0.68 ± 0.04a,c 0.96 ± 0.09d
GLUT 4 1.00 ± 0.08d 0.89 ± 0.09 0.95 ± 0.07 0.97 ± 0.06
DBT or rosiglitazone was dissolved in distilled water for oral administration at the desired doses in a volume of 10mLkg−1 once a day into rats receiving
6 weeks of fructose chow feeding. The vehicle (distilled water) used to dissolve the tested medications was given at the same volume. Values (mean ± SD)
were obtained from each group of ﬁve animals. aP <. 05 and bP <. 01 compared with the values of vehicle-treated standard chow-fed rats in each group,
respectively. cP <. 05 and dP <. 01 compared with the values of vehicle-treated fructose chow-fed rats in each group, respectively.
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Figure 3: Representative immunoblotsof insulin-stimulated phosphorylation of insulin receptor (a) and insulin receptor substrate-1 (b) in
the soleus muscles of fructose chow-fed rats after repeated oral administration of DBT (2.5gkg−1 per day) or rosiglitazone (4mgkg−1 per
day) for 14 days. Rats that did not receive any treatment were given the same volume of vehicle (distilled water) used to dissolve the test
medications. Findings were reproduced on four separate occasions. Quantiﬁcation of protein levels expressed as mean with SD (n = 5p e r
group) in each column. aP <. 05 and bP <. 01 represents the level of signiﬁcance compared with the values with vehicle-treated standard
chow-fed rats, respectively.
48% of that in standard chow-fed group. The expression of
p85 regulatory subunit of PI 3-kinase in soleus muscles was
increased after fructose chow-fed animals receiving 2 weeks
of rosiglitazone (4mgkg−1 p e rd a y )o rD B T( 2 . 5gk g −1 per
day; Figure 2, Table 2).
Two-week treatment with rosiglitazone (4mgkg−1 per
day) signiﬁcantly improved the insulin-stimulated state of PI
3-kinase associated with IRS-1 in soleus muscles of fructose
chow-fed rats (Figure 4). Although the degree of insulin-
stimulated association between PI 3-kinase and IRS-1 in
soleus muscle of DBT-treated fructose chow-fed rats was still
loweredinrelationtovaluesfromthoseofstandardchow-fed
animals, which was increased to 1.6-fold of that from their
vehicle-treated counterparts (Figure 4).
3.6. The Protein Levels and the Degree in Insulin-Stimulated
Phosphorylation of Akt. The expression of Akt protein in
soleus muscles of fructose chow-fed rats was lower than
that in standard chow-fed group (Figure 2, Table 2). After 2
weeksofrosiglitazone (4mgkg−1 perday)treatment, theAkt
protein expression in soleus muscle offructose chow-fed rats
was returned to that for standard chow-fed group (Figure 2,
Table 2). It observed that 2-week DBT (2.5gkg−1 per day)
treatment elevated Akt protein level in soleus muscles of
fructose chow-fed rats to 1.5-fold of that from their vehicle-
treated counterparts (Figure 2, Table 2).
Insulin-stimulated phosphorylation of Akt on both
Thr
308 and Ser473 in soleus muscles of fructose chow-fed
rats receiving 2 weeks of rosiglitazone (4mgkg−1 per day)Evidence-Based Complementary and Alternative Medicine 7
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Figure4:Representative immunoblotsofthePI3-kinaseassociated
with IRS-1 in insulin-stimulated soleus muscles of fructose chow-
fed rats receiving oral administration of DBT (2.5gkg−1 per day)
or rosiglitazone (4mgkg−1 per day) for 14 days. Rats that did
not receive any treatment were given the same volume of vehicle
(distilledwater) usedto dissolvethetestmedications.Findings were
reproduced on four separate occasions. Quantiﬁcation of protein
levels expressed as mean with SD (n = 5 per group) in each
column. aP <. 05 and bP <. 01 represents the level of signiﬁcance
compared to thevalues withvehicle-treated standardchow-fed rats,
respectively.
treatment were increased to nearly 2-fold of those from
theirvehicle-treatedcounterparts(Figure 5).Two-week DBT
(2.5gkg−1 per day) treatment also enhanced the phosphory-
lation degree of Akt tyrosine (Thr
308)a n dA k ts e r i n e( S e r 473)
in soleus muscles of fructose chow-fed animals in response
to insulin-stimulation (Figure 5).
3.7. The Protein Levels and the Degree in Insulin-Stimulated
Phosphorylation of AS160. The protein content of AS160 in
soleusmuscleoffructosechow-fedratswasdepressed to40%
of that in standard chow-fed group; 2-week treatment with
rosiglitazone (4mgkg−1 per day) elevated AS160 expression
in soleus muscle of fructose chow-fed rats close that of
standard chow-fed rats (Figure 2, Table 2). The depressed
protein level of AS160 in soleus muscles of fructose chow-
fed rats was increased after 2-week DBT (2.5gkg−1 per day)
treatment although not to the levels of standard chow-fed
group (Figure 2, Table 2).
The phosphorylation of AS160 induced by insulin was
markedly elevated in soleus muscles of fructose chow-fed
rats receiving 2 weeks of rosiglitazone (4mgkg−1 per day;
Figure 6). Two-week DBT(2.5gkg−1 per day) treatment also
raised the degree of phosphorylation of AS160 in soleus
muscles of fructose chow-fed rat in response to insulin
stimulation (Figure 6).
3.8. The Protein Levels and Insulin-Stimulated Translocation
of GLUT 4. Although the total GLUT 4 protein in soleus
muscles of fructose chow-fed rats was lower than that in
standard chow-fed group, there was no signiﬁcant diﬀerence
(Figure 2). The expression of total GLUT 4 protein in soleus
muscles was raised in fructose chow-fed rats after 2 weeks of
treatment, but the changes induced by neither rosiglitazone
nor DBT was diﬀerent from those of their vehicle-treated
counterparts (Figure 2).
Insulin-stimulated GLUT 4 protein expression in the
membrane fraction of soleus muscle from fructose chow-fed
rats was only about 30% of that in standard chow-fed rats;
conversely, GLUT 4 protein content in the cytosolic fraction
ofthesame sample was about1.6-foldofthatobservedin the
standard chow-fed group (Figure 7). In fructose chow-fed
animals receiving 2-week rosiglitazone (4mgkg−1 per day)
treatment, insulin-stimulated GLUT 4 protein expression
in the membrane fraction of soleus muscles was increased
to achieve the level as in the standard chow-fed group,
but the GLUT 4 protein level in the cytosolic fraction of
same sample was at 60% of the level of their vehicle-
treated counterparts (Figure 7). At the termination of 2-
week DBT (2.5gkg−1 per day) treatment, insulin-stimulated
GLUT 4 protein expression in the membrane fraction of
soleus muscles from fructose chow-fed animals increased to
about 1.8-fold of those from the level of their vehicle-treated
counterparts, whereas the amount of GLUT 4 protein in the
cytosolic fraction of the soleus muscles from fructose chow-
fed animals was changed to 70% of that observed in their
vehicle-treated counterparts (Figure 7).
4.Discussion
Increasing consumption of dietary fructose could be one of
the factors responsible for the development of obesity and
the accompanying insulin resistance syndrome [10]. It has
beenestablishedthat insulin resistance, impaired glucosetol-
erance, hyperinsulinemia, hypertension and hyperlipidemia
are associated with fructose intake in animal models [10].
The duration of high fructose feeding and the lipid content
and type of the diets lead to discrepancies in the degree of
insulin resistance and in the metabolic parameters. In this
study, an increase in plasma glucose level associated with
hyperinsulinaemia deﬁnitively suggests impaired insulin
action on glucose regulation in 6-week fructose chow-fed
rats. Two-week treatment regimen with DBT was found to
signiﬁcantly decrease the high plasma glucoseconcentration,
but in contrast to the eﬀect of rosiglitazone made less
eﬀect on the modiﬁcation of dyslipidemia in fructose-
induced insulin resistance. It seems that the major action
of DBT in insulin-resistant rats might not be associated
with controlling in synthesis and/or metabolism of lipid,
regulation of the insulin-glucose axis represents an obvious
factor in the assessment of the mechanism(s).
The degree of insulin resistance was found to be higher
in rats fed with 6-week fructose chow as indicated by
ah i g h e rH O M A - I R[ 12]. Compared to HOMA-IR index
based on measurements of basal glucose and insulin, the
ISIcompprovidesareasonableapproximationofwhole-body
insulin sensitivity that represents a composite of hepatic
and peripheral tissues and takes into consideration insulin
sensitivity both in the basal state and after the ingestion of8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Representative immunoblots of insulin-stimulated phosphorylation of Akt on both Thr
308 (a) and Ser
473 (b) in soleus muscles
of fructose chow-fed rats receiving oral administration of DBT (2.5gkg−1 per day) or rosiglitazone (4mgkg−1 per day) for 14 days. Rats
that did not receive any treatment were given the same volume of vehicle (distilled water) used to dissolve the test medications. Findings
were reproduced on four separate occasions. Quantiﬁcation of protein levels expressed as mean with SD (n = 5 per group) in each column.
aP <. 05 and bP <. 01 represents the level of signiﬁcancecompared with the values with vehicle-treated standard chow-fed rats, respectively.
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Figure 6: Representative immunoblots of insulin-stimulated phos-
phorylation of AS160 in the soleus muscles of fructose chow-
fed rats receiving oral administration of DBT (2.5gkg−1 per day)
or rosiglitazone (4mgkg−1 per day) for 14 days. Rats that did
not receive any treatment were given the same volume of vehicle
(distilledwater) usedto dissolvethetestmedications.Findings were
reproduced on four separate occasions. Quantiﬁcation of protein
levels expressed as mean with SD (n = 5 per group) in each
column. aP <. 05 and bP <. 01 represents the level of signiﬁcance
compared with the values with vehicle-treated standard chow-fed
rats, respectively.
a glucose load [12, 14]. Although the reduced HOMA-IR
valuecouldsupportthefactthatinsulinresistanceinfructose
chow-fed rats was ameliorated by 14-day DBT treatment,
DBT was found to increase whole-body insulin sensitivity in
fructose chow-fed rats as evidenced by the marked elevation
of ISIcomp in these animals after 2-week administration, as
did rosiglitazone treatment. Clearly, these results imply that
DBT has the ability to reverse the impaired responsiveness to
insulin in insulin-resistant rats, demonstrating the insulin-
sensitizing eﬀect of the formula.
Skeletal muscle insulin resistance is a salient feature of
type-2 diabetes. In humans and other mammals, skeletal
muscle normally accounts for about 75% of whole body
insulin-stimulated glucose transport [17]. Impaired ability
of the muscle to respond to insulin is therefore disruptive to
systemic glucose homeostasis. It has been documented that
insulin action on glucose uptake and metabolism is much
greater in skeletal muscle composed primarily of oxidative
ﬁbers (e.g., the soleus) as compared with glycolytic ﬁbers
(e.g., the epitrochlearis and extensor digitorum longus),
even though the soleus muscle represents a small portion
of the total muscle mass [18]. Actually, the increase in
insulin action on skeletal muscle is likely to be related to
increased protein expression-and/or functional activity of
several key components of the insulin signal transduction
cascade. Defects in the insulin signaling cascade leading
to impaired glucose utilization are believed to play a key
role in the pathogenesis of insulin resistance [19]. It is
conceivable that IRS-1 tyrosine phosphorylation in response
to insulin stimulation generally increases the association of
IRS-1 with the PI 3-kinase, resulting in increased PI 3-kinase
activity, which in turn leads to activation of serine/threonine
kinase protein B (PKB or Akt) and, ultimately, to an
enhancement in insulin-stimulated glucose disposal [20].Evidence-Based Complementary and Alternative Medicine 9
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Figure 7: The autoradiograph resulting from Western blot analysisof representative protein levels for glucose transporter subtype 4 (GLUT
4) in the membrane (a) and cytosolic (b) fractions of soleus muscle from fructose chow-fed rats responded to insulin stimulation following
repeatedly oral administration of DBT (2.5gkg−1 per day) or rosiglitazone (4mgkg−1 per day) for 14 days. Rats that did not receive any
treatment were given the same volume of vehicle (distilled water) used to dissolve the test medications. Similar results were obtained with
an additional four replications. Quantiﬁcation of protein levels expressed as mean with SD (n = 5 per group) in each column. aP <. 05 and
bP <. 01 represents the level of signiﬁcance compared to the values with vehicle-treated standard chow-fed rats, respectively.
Therefore, we proposed that any observed increases in IRS-
1 related signals in soleus muscles of fructose chow-fed rats
after DBT treatment would provide strong evidence for the
beneﬁcial eﬀects on the amelioration of impaired insulin
action. With this aim in mind, soleus muscle samples were
prepared from all animals after insulin stimulation.
Similar to the eﬀect of rosiglitazone treatment, the
impaired insulin action on IRS-1 tyrosine phosphorylation
or IRS-1-associated PI 3-kinase activity in soleus muscle
of fructose chow-fed rats has been improved by repeated
treatment with DBT. Actually, phosphorylation of Akt on
both Thr
308 and Ser473 is required for maximal activation
[21]. Two-week DBT treatment was found to signiﬁcantly
increase the protein levels of Akt accompanied to elevate
insulin action on phosphorylation of Akt on both Thr308
and Ser473 in soleus muscles of fructose chow-fed rats. Here
we show that the DBT-mediated recovery of insulin action
was related to the improvement in IRS-1/PI 3-kinase/Akt
signaling pathwayin insulin-resistant soleus muscle.It seems
possible that the eﬀect of DBT on the improvement of post-
receptorinsulin signaling inducedthe subsequentincrease in
insulin sensitivity.
Considering that the regulation of glucose uptake into
muscle cells via GLUT 4 is a fundamental action of insulin,
andthisprocessisimpairedintype-2diabetes[22],weexam-
ined the expression and translocation of GLUT 4 protein in
soleus muscle. It was found that the protein levels of total
GLUT 4 were not signiﬁcantly reduced in soleus muscle of
fructose chow-fed rats as relative to the normal control rats;
this is consistent with the previous study demonstrating that
alterations in GLUT 4 expression are not a primary cause for
the development of insulin resistance [22]. Our data shows
that rosiglitazone or DBT had no signiﬁcant eﬀect on whole-
muscle expression of GLUT 4 protein in fructose chow-fed
rats, but there was a deﬁnite improvement in the defective
insulin action on GLUT 4 translocation from intracellular
vesicles to the plasma membrane of soleus muscle given
in fructose chow-fed rats by DBT treatment. Although the
eﬀect of DBT on the translocation of GLUT 4 protein in
insulin-resistant soleus muscle was not as eﬀective as that
produced by rosiglitazone, based on the above ﬁndings, we
considered that the eﬀect of DBT on improvement in insulin
sensitivity may be attributable to restored insulin signaling
cascade involved in the regulation of the recruitment of
GLUT 4 transporters from intracellular reserves and their
subsequent insertion into the plasma membrane, thereby
leading to increase glucose delivery into skeletal muscle.
Thereisconsiderableevidencethatinresponsetoinsulin,
phosphorylation of a recently identiﬁed protein, known as
Akt substrate of 160 kDa (AS160), correlated signiﬁcantly
with IRS-1 and Akt phosphorylation and associated with
accelerated rates of GLUT 4 translocation, such that GLUT
4 manifests predominantly at the cell surface and enhances
insulin-stimulated glucose transport [23]. Similar to the
eﬀect of rosiglitazone, DBT was found to increase insulin-
stimulated AS160 phosphorylation on PAS motifs in soleus
muscles of fructose chow-fed rats. It seems that not only
the impaired insulin-mediated phosphorylation, but also10 Evidence-Based Complementary and Alternative Medicine
the defect in the protein expression involved in the IRS-1/PI
3-kinase/Akt/AS160 arm of the insulin signaling pathway
was improved in soleus muscle of 2-week DBT-treated
fructose chow-fed rats. It raised the possibility that the DBT-
mediated action on the improvement of insulin sensitivity
in fructose chow-fed rats may be associated with a point of
the post-receptor insulin signaling for increasing cell surface
GLUT 4 and glucose transport. It has been documented
that rosiglitazone can sensitize AMP-activated protein kinase
(AMPK) mediated glucose disposal in peripheral tissues
under insulin-resistant states [24]. Although further studies
are needed to determine whether the insulin-sensitizing
eﬀect of DBT is mediated through the action of the AMPK
pathway, our ﬁndings provide a new insight to the pharma-
cological beneﬁts of DBT, which displays the characteristics
of rosiglitazone, retaining its insulin sensitization potential
but, unlike rosiglitazone, does not cause any increase in
body weight. Administration of DBT may be a suitable
therapeutic adjunct for the treatment of insulin resistant
patients and/or the patients who are particularly sensitive to
the common TZD-induced side eﬀects of weight gain and
edema.
Following the most general principles of TCM, diabetes
aﬀects a patient’s “qi (energy/life-force)” and cause weakness
in circulatory system function. In TCM, the spleen is a
source of vital energy and blood and a controller of blood
circulation. When spleen qi is weak, its blood controlling
function is disturbed; furthermore, the production of blood
and qi are decreased. Treatment of diabetes by the principles
of TCM therefore emphasizes improvements of “qi” and
circulatory function [25]. In view of the ﬁndings presented
in this report, the preparation known as DBT possesses the
potentialtoaccomplishtheseobjectives.MostTCMremedies
are prepared as solutions and formulatedto contain diﬀerent
herbs in combination. The ratio of Radix A. sinensis and
Radix Astragali used in DBT should be 1:5 as described in
China in 1247 AD; however, the rationale of this formula has
not been given. It has been documented that higher amounts
ofRadix A. sinensis-derived ferulic acid, and Radix Astragali-
derived astragaloside IV, calycosin, and formononetin were
found in DBT with Radix A. sinensis and Radix Astragali in
1:5 ratio [26]. Further studies will be required to identify
the ingredients and/or identiﬁed chemicals in DBT that is
responsible for the beneﬁcial eﬀects observed in the present
study.
It should be noted that the scientiﬁc basis for the
therapeutic eﬀects of TCM, which utilizes herbs for therapy
under the guidance of traditional theory, has not been
established in the literature. The ﬁndings of the present
study are of merit in revealing, for the ﬁrst time, that DBT
possesses the potential to reverse the inability of insulin to
act on soleus muscle of rats receiving fructose-rich chow.
The beneﬁcial eﬀects of DBT on improvements in whole-
body insulin sensitivity are associated with amelioration
of defective insulin action on speciﬁc post-receptor insulin
signaling related to IRS-1-associated PI 3-kinase step and
GLUT 4 translocation. This preparation may therefore
prove useful as adjuvant therapy in the treatment of
diabetes.
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